As UnitedHealth Group (UNH) approaches its Q1 2026 earnings report, investor sentiment is mixed with expectations of an 8% decline in earnings per share. Despite its year-to-date stock drop of nearly 17% due to rising medical costs and regulatory issues, analysts view UNH stock as potentially undervalued at around $354, with hopes for gains if earnings surprise positively. Additionally, the company is set to raise its full-year EPS guidance and invest significantly in AI initiatives, creating a bullish outlook amidst ongoing Medicare challenges.
“UnitedHealth Group $UNH closed today at $323.48, down 0.35%, as investors anticipate the company's first-quarter 2026 earnings report scheduled for tomorrow.”
“Analysts anticipate an 8% year-over-year decline in Q1 EPS to $6.58, with revenue around $109.43 billion, reflecting medical cost and Medicare Advantage concerns.”
“$UNH stock has faced significant pressure year-to-date, down nearly 17% due to rising medical costs and Medicare Advantage regulatory uncertainties.”
“He’s intrigued by $UNH and says it 'may be a good time to get in,' adding that the stock can move quickly.”
“$UNH ER is in premarket tomorrow, going to position for $350 calls small here into tomorrow end of this week expiration, this is a $500+ stock trading at a discount and if they is a nice improvement which I think there could be, this gaps up to $400+ this week otherwise may stay flat. Risky but worth it for me.”
“$UNH ER is in premarket tomorrow, going to position for $350 calls small here into tomorrow end of this week expiration, this is a $500+ stock trading at a discount and if they is a nice improvement which I think there could be, this gaps up to $400+ this week otherwise may stay flat. Risky but worth it for me.”
“$UNH reports before the market opens tomorrow. Market is optimistic and there has been a bullish move leading to Earnings.”
“UnitedHealth Group (UNH) has shown strong Q1 performance, raising its full-year earnings guidance amid a positive earnings season.”
“Analysts are optimistic about its turnaround, following a significant market dip last year.”
“Jim Cramer Says UNH at $354 Is a Steal — Here's Why the Math Backs Him Up.”
“Raymond James analyst John Ransom raised the firm’s price target on UnitedHealth (UNH) to $370 from $330 and keeps an Outperform rating on the shares.”
“UnitedHealthcare supports effort to standardize prior authorization rules.”
